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Abstract Oxidation of low-density lipoproteins (LDL)
promotes atherosclerosis by enhancing vascular inflamma-
tion and foam cell formation. The corollary is that diets that
stimulate endogenous anti-oxidants may protect against
atherosclerosis. This review focuses on sulforaphane, an
isothiocyanate derived from green vegetables, which
induces multiple anti-oxidant enzymes via activation of a
transcription factor called Nrf2. Although studies of
cultured cells and experimental animals revealed that
sulforaphane can suppress inflammatory activation of
vascular cells, the potential beneficial effects of sulfora-
phane in atherosclerosis have not been studied directly. A
deeper understanding of vascular responses to sulforaphane
may inform nutritional approaches to prevent vascular
inflammation and atherosclerosis.
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The influence of oxidants and antioxidants
on the development of atherosclerosis
Atherosclerosis is a lipid-driven chronic inflammatory
disease [1–4] in which accumulation of cells, lipids and
extracellular matrix in the wall of an artery can result in
occlusion of the vessel lumen and lead to angina, heart
attack or stroke. A critical step in lesion formation is the
oxidation of LDL to generate a family of covalent
modifications. Oxidised LDL (oxLDL) particles influence
atherosclerosis by altering the physiology of endothelial
cells (EC), macrophages and other cell types. They promote
the recruitment of leukocytes from the bloodstream to the
arterial wall by triggering EC expression of adhesion proteins,
chemokines and other pro-inflammatory molecules [5–7].
This process involves multiple inflammatory signalling
events including induction of intracellular reactive oxygen
species (ROS) [6, 8], activation of p38 and ERK MAP
kinases [8–10], and activation of the transcription factors
NF-κB [6, 11] and STAT3 [7]. Moreover, evidence from our
group and others suggests that ROS promote inflammatory
activation in part by inactivating enzymes that negatively
regulate inflammatory pathways [12–14]. Induction of ROS
by oxLDL can also induce EC apoptosis [15–17], and
influence vascular tone through uncoupling of eNOS from
nitric oxide production [18, 19]. OxLDL can also influence
the physiology of macrophages which recognise and
internalise oxLDL via scavenger receptors (e.g. CD36,
Scavenger Receptor class A (SRA)) [20–23]. Binding of
oxLDL to CD36 or SRA initiates a signalling cascade that
includes MAP kinase and NF-κB activation [20, 24–28],
which drives expression of inflammatory genes. Although
clearance of oxLDL by macrophages maintains vascular
homeostasis by preventing oxLDL build up, persistent
phagocytosis leads to accumulation of intracellular lipids.
This process creates activated foam cells that drive athero-
genesis by generating oxidant moieties, secreting pro-
inflammatory proteins, expressing thrombogenic factors
and releasing toxic lipids [2–4].
Biological antioxidants are broadly divided into direct and
indirect antioxidants. Direct antioxidants either absorb free
radicals (e.g. vitamin E) or transfer electrons in redox-
exchange (e.g. vitamin C). Indirect antioxidants, primarily
phytochemicals, alter cellular physiology by inducing anti-
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oxidant genes (e.g. heme oxygenase-1 (HO-1), ferritin,
thioredoxin, thioredoxin reductase 1, glutathione, superoxide
dismutase). Given the central importance of oxidation in
atherogenesis, it has been proposed that antioxidants may
protect arteries from lesion formation [29–31]. There are
several lines of evidence to support this idea: (1) epidemi-
ological studies correlate the consumption of fruit and
vegetables rich in anti-oxidants with protection from
cardiovascular disease [29–31], (2) in vitro studies revealed
that antioxidants exert “anti-atherogenic” effects including
suppression of pro-inflammatory activation of EC [32–36]
and macrophages [37–39] and inhibition of vascular smooth
muscle cell (VSMC) proliferation [40, 41], (3) genetic
deletion of antioxidant genes including hemoxygenase-1
(HO-1) [42] and glutathione peroxidase-1 [43] can enhance
experimental atherosclerosis, while overexpression of HO-1
[44], thioredoxin [45] or catalase [46] reduces lesion
formation, (4) a polymorphism in the promoter of the
(antioxidant) HO-1 gene is associated with elevated risk of
coronary heart disease in man [47, 48]. The potential utility
of antioxidants as therapeutics for the prevention or
treatment of atherosclerosis has received considerable atten-
tion. However, clinical trials of dietary supplementation with
vitamin E did not reveal beneficial effects on cardiovascular
health in the general population [30, 31], but gave promising
results in some groups of patients with enhanced oxidative
load associated with existing coronary artery disease [49] or
end-stage renal disease [50]. In view of the disappointing
results of direct antioxidants in clinical trials, we suggest that
therapeutic strategies aimed at inducing anti-oxidant
enzymes indirectly may be more effective. This concept is
consistent with studies of probucol, a drug with both lipid-
lowering and indirect anti-oxidant effects, which suppressed
atherosclerosis in pre-clinical [51, 52] and clinical trials [53,
54]. Importantly, comparison of probucol with control
derivatives that retain its anti-oxidant effects but not lipid-
lowering effects, indicate that probucol’s atheroprotective
activity is primarily due to induction of anti-oxidant enzymes
in vascular cells [55].
Sulforaphane is an indirect dietary antioxidant
Sulforaphane is a biologically active dietary isothiocyanate
that is derived from vegetables in the Brassica genus (e.g.
broccoli, brussel sprouts, cauliflower, Pak Choi). Recent
studies revealed that sulforaphane alters cellular physiology,
at least in part, by functioning as an indirect anti-oxidant.
This property of sulforaphane is mediated via activation of
the transcription factor Nrf2 which is a central regulator of
cellular redox [56, 57]. In unstimulated cells, Nrf2 is
suppressed by kelch-like ECH-associated protein 1 (Keap1)
which targets it for ubiquitination and proteasomal process-
ing. Nrf2 can be activated by sulforaphane and other
physiological stimuli which disrupt Keap1-Nrf2 interactions
leading to stabilisation and nuclear translocation of Nrf2 [56,
57] (Fig. 1). Following its activation, Nrf2 binds to
electrophilic response elements (otherwise known as antiox-
idant response elements) and induces numerous antioxidants
including HO-1, ferritin, thioredoxin, thioredoxin reductase
1 and MnSOD [56–59].
The protective effects of sulforaphane on vascular
physiology
The concept that consumption of green vegetables can
prevent cardiovascular disease is consistent with epidemi-
ological studies that revealed that dietary intake of broccoli
and related vegetables is associated with reduced risk of
Fig. 1 Regulation and function of Nrf2. Nrf2 is a transcription factor
that induces numerous antioxidants (e.g. hemoxygenase-1 (HO-1),
thioredoxin (TRX1), ferritin heavy chain (FHC)), 26S proteasome
subunits, heat shock proteins and other protective molecules. In
unstimulated cells, Nrf2 is inactivated by Keap1 which sequesters
Nrf2 in the cytoplasm and targets Nrf2 for ubiquitination and
degradation. Nrf2 can be activated by several stimuli (e.g. reactive
oxygen species, hypoxia, sulforaphane) that interfere with Nrf2-Keap
1 interaction
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coronary heart disease mortality [60–63]. It also consistent
with the observation that ingestion of broccoli can reduce
oxidation and inflammation in arteries of spontaneously
hypertensive stroke-prone rats [64]. Pharmacokinetic stud-
ies in humans that revealed that consumption of a single
portion of broccoli cress (a particularly rich source of
sulforaphane) or mature broccoli can generate plasma
sulforaphane concentrations of approximately 1 μM [65,
66] and 60 nM [67], respectively. Plasma sulforaphane
concentrations subsequently declined with first-order kinet-
ics (1.77 h half life) to reach low nM concentrations within
several hours [65–67]. Although sulforaphane is rapidly
cleared from plasma, it is plausible that it may have
prolonged effects on vascular physiology as consumption
of broccoli can induce antioxidant enzymes for at least 24 h
in healthy volunteers [68, 69]. In vitro studies revealed that
concentrations of sulforaphane that can be achieved in
plasma through consumption of Brassica vegetables can
influence the physiology of vascular and inflammatory cells
[70–75], suggesting that green vegetable intake may
prevent cardiovascular disease in part via generation of
sulforaphane.
We recently studied the effects of shear stress and
sulforaphane on endothelial activation in aortae of mice
challenged with lipopolysaccharide (LPS) [70]. Vascular
inflammation and atherosclerosis develop predominantly at
branches and bends of arteries which are exposed to non-
uniform blood flow which exerts relatively low shear stress
on vascular endothelium, whereas regions of arteries that
are exposed to high shear stress are protected [76, 77]. Pro-
inflammatory activation of EC is reduced at high shear sites
compared to low shear regions, thus providing a potential
explanation for the distinct spatial localisation of lesions
[70, 78, 79]. Our findings revealed that high shear stress at
atheroprotected sites reduced key measures of EC inflam-
matory activation, p38 MAP kinase activation and VCAM-
1 expression, by activating Nrf2 [70] (Fig. 2). By contrast,
EC at a low shear, atherosusceptible site contained inactive
(cytoplasmic) Nrf2 and were prone to pro-inflammatory
activation. We therefore examined whether pharmacologi-
cal activation of Nrf2 using sulforaphane would suppress
inflammation at susceptible sites. In cultured EC, sulfor-
aphane suppressed p38 activation, VCAM-1 expression and
ROS production via Nrf2 [70, 71]. Similarly, sulforaphane
suppressed p38 activation and VCAM-1 expression at
atherosusceptible sites in wild-type but not in Nrf2-/- mice,
indicating that the anti-inflammatory effects of sulfora-
phane were Nrf2-dependent [70] (Fig. 2). Thus our
observations reveal that inflammation at atherosusceptible
regions can be prevented by sulforaphane-mediated activa-
tion of Nrf2.
Given observations from our group and others that Nrf2
and its target genes can protect against vascular inflamma-
tion [42, 43, 70] it would be expected that ablation of Nrf2
would exaggerate atherosclerosis. Consistent with this,
Levonen et al. demonstrated that Nrf2 overexpression in
the rabbit aorta reduces inflammation in response to injury
[80]. However, paradoxically, a recent report points in the
opposite direction, with genetic deletion of Nrf2 suppress-
ing CD36-dependent uptake of modified LDL by macro-
phages and reducing lesion development in an
atherosusceptible strain of mice [81]. This latter study does
not however preclude a protective role for Nrf2 during the
initiation of atherosclerosis because: (1) early stages of
atherogenesis were not studied, (2) the model studied is
severe and any protective effects of Nrf2 may have been
overwhelmed by the high atherogenic drive. Similarly,
although sulforaphane can protect arteries from inflamma-
tion, this compound may have deleterious effects on
vascular health at high concentrations, e.g. although low
concentrations (<1 μM) of sulforaphane can reduce
inflammatory activation of EC without altering viability
[70, 71], very high concentrations (>10 μM) can trigger EC
apoptosis [82–84]. High concentrations of sulforaphane can
also induce CD36 in macrophages [85] and therefore may
potentially influence the formation of foam cells which play
Fig. 2 Model—Consumption of Brassica vegetables may prevent
vascular inflammation at atherosusceptible sites. Regions of arteries
with relatively uniform geometry are protected from inflammation and
atherosclerosis by high shear stress which activates Nrf2. By contrast,
branches and bends that are exposed to low, oscillatory shear stress are
susceptible to lesion formation. However, dietary consumption of
Brassica vegetables may prevent branches and bends from inflamma-
tion by activating Nrf2 in endothelial cells
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a central role in atherogenesis. Thus it will be important in
future studies to assess directly whether relatively low
concentrations of sulforaphane (achievable through con-
sumption of green vegetables) can prevent atherosclerosis,
without triggering potential deleterious effects on EC
viability.
Outlook
There is now strong evidence to suggest that regular
consumption of Brassica vegetables may provide a preven-
tative dietary approach to reduce cardiovascular disease
risk. This has been obtained partly through epidemiological
studies that correlated green vegetable intake with protec-
tion. The idea is also consistent with the observation that
plasma concentrations of sulforaphane that can be achieved
by consumption of green vegetables are sufficient to
suppress inflammatory activation of arteries. Clinical trials
should now be carried out to test directly whether
consumption of green vegetables or bioactive derivatives
(e.g. sulforaphane) can prevent the initiation and progres-
sion of atherosclerosis. This idea is currently being pursued
through a study that will investigate the effects of a diet rich
in broccoli on plasma cholesterol levels, blood pressure and
augmentation index and pulse wave velocity (measures of
arterial stiffness) in subjects with elevated cardiovascular
risk (ClinicalTrials.gov identifier NCT01114399). In addi-
tion to their scientific value, trials of this nature may also
provide value in terms of public perception by reinforcing
guidelines that eating fruit and vegetables can prevent
cardiovascular disease.
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